Table 2.
Multivariate analysis of factors associated with overall survival (OS) and progression-free survival (PFS) in the pooled cohort.
| Parameter | OS | PFS | ||
|---|---|---|---|---|
| HR (95% CI) | p Value | HR (95% CI) | p Value | |
| LIPI Group | ||||
| Good (0) | 1.0 (reference) | 1.0 (reference) | ||
| Intermediate (1) | 1.8 (1.4–2.3) | <0.001 | 1.3 (1.0–1.7) | 0.019 |
| Poor (2) | 3.6 (2.5–5.1) | <0.001 | 3.0 (2.0–4.5) | <0.001 |
| Cohort | ||||
| NSCLC | 1.0 (reference) | 1.0 (reference) | ||
| RCC | 0.6 (0.5–0.8) | 0.002 | 1.1 (0.8–1.4) | 0.65 |
| Melanoma | 0.8 (0.6–1.1) | 0.18 | 0.9 (0.7–1.3) | 0.68 |
| Age | ||||
| <70 | 1.0 (reference) | 1.0 (reference) | ||
| ≥70 | 0.9 (0.7–1.2) | 0.60 | 1.0 (0.8–1.2) | 0.83 |
| Treatment Line | ||||
| 1 | 1.0 (reference) | 1.0 (reference) | ||
| ≥2 | 1.7 (1.2–2.1) | <0.001 | 1.3 (1.0–1.8) | 0.040 |
| ECOG PS | ||||
| <2 | 1.0 (reference) | 1.0 (reference) | ||
| ≥2 | 2.3 (1.8–3.0) | <0.001 | 1.7 (1.2–2.2) | <0.001 |
CI: confidence interval, ECOG PS: Eastern Cooperative Oncology Group performance status HR: hazard ratio, LIPI: lung immune prognostic index, OS: overall survival, PFS: progression-free survival.